HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Slovakian Government Rejects CBD Decriminalization

Executive Summary

Cannibidiol (CBD) remains a scheduled drug in Slovakia after the country's parliament rejected a recent proposal to decriminalize the substance. 

You may also be interested in...



Slovakia Down-Schedules CBD As WHO Insists It Is Not A Narcotic

As a recent meeting of the United Nation's Commission on Narcotic Drugs, the World Health Organization recommended that CBD products with no more than 0.2% THC should not be considered controlled substances. In response, Slovakia down-scheduled CBD. The move and the discussion sparked by WHO's recommendation within the UN 's drug commission shines a new light on debates raging in the UK, where industry is currently facing claims that CBD products with any levels of THC whatsoever should be considered a controlled substance.

COVID-19 Drives UK Consumers To Pharmacy And E-Commerce – J&J Survey

UK consumers are looking to pharmacy for help with selecting OTCs during the coronavirus pandemic, as well as turning increasingly to e-commerce, finds a recent survey by Johnson & Johnson Consumer Health.

UK CBD Industry Welcomes FSA Clarification On Novel Food Evidence Requirement

“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry. 

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel